The clinical implications of the current study and future ones might include a new stratification of RMS patients with metastatic disease according to the levels of secreted IGFBP2 and anti-IGFBP2 antibodies and a further characterization of liquid biopsies in pediatric cancer patients. This evidence concerns the gene IGFBP2 and metastatic neoplasm.